Literature DB >> 20195805

Development and characterization of enteric-coated immediate-release pellets of aceclofenac by extrusion/spheronization technique using kappa-carrageenan as a pelletizing agent.

Vaishali A Kilor1, Nidhi P Sapkal, Jasmine G Awari, Bharti D Shewale.   

Abstract

In the present study, an attempt was made to prepare immediate-release enteric-coated pellets of aceclofenac, a poorly soluble nonsteroidal anti-inflammatory drug that has a gastrointestinal intolerance as its serious side effect. Formulation of enteric-coated pellets with improved solubility of aceclofenac could address both of these problems. To achieve these goals, pellets were prepared by extrusion-spheronization method using pelletizing agents that can contribute to the faster disintegration and thereby improve the solubility of the drug. Different disintegrants like beta-cyclodextrin, kollidon CL, Ac-Di-Sol, and sodium starch glycolate were tried in order to further improve disintegration time. The pellets were characterized for drug content, particle size distribution, flow properties, infrared spectroscopy, surface morphology, disintegration rate, and dissolution profile. The formulations, which showed best disintegration and dissolution profiles, were coated with Eudragit L100-55, an enteric-coated polymer which does not dissolve at gastric pH but dissolves at intestinal pH, releasing the drug immediately in the dissolution medium. The optimized enteric-coated formulation containing 20% kappa-carrageenan, lactose, and sodium starch glycolate as a disintegrant did inhibit the release of the drug for 2 h in 0.1 N HCl, whereas 87% of the drug was released within 45 min. The improvement was substantial when it was compared with solubility of pure drug under the same conditions. Thus, dissolution profiles suggested that combination of kappa-carrageenan and sodium starch glycolate resulted into fast-disintegrating, immediate-release pellets, overcoming the bioavailability problem of the poorly soluble drug, aceclofenac, and enteric coating of these pellets avoids the exposure of aceclofenac to ulcer-prone areas of the gastrointestinal tract.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20195805      PMCID: PMC2850460          DOI: 10.1208/s12249-010-9389-9

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  9 in total

1.  Aceclofenac blocks prostaglandin E2 production following its intracellular conversion into cyclooxygenase inhibitors.

Authors:  R Yamazaki; S Kawai; T Matsuzaki; N Kaneda; S Hashimoto; T Yokokura; R Okamoto; T Koshino; Y Mizushima
Journal:  Eur J Pharmacol       Date:  1997-06-25       Impact factor: 4.432

2.  Trials of clear aceclofenac-loaded soft capsules with accelerated oral absorption in human subjects.

Authors:  Chul Soon Yong; Yu-Kyoung Oh; Kyung Hee Lee; Sang-Man Park; Young-Joon Park; Young Sig Gil; Chang Hun Yu; Bong-Kyu Yoo; Jong Soo Woo; Jong Oh Kim; Jong-Dal Rhee; Chong-Kook Kim; Han-Gon Choi
Journal:  Int J Pharm       Date:  2005-09-30       Impact factor: 5.875

3.  Physicochemical characterization of meloxicam-mannitol binary systems.

Authors:  Parya Reisi Nassab; Róbert Rajkó; Piroska Szabó-Révész
Journal:  J Pharm Biomed Anal       Date:  2006-04-18       Impact factor: 3.935

4.  Use of kappa-carrageenan as alternative pelletisation aid to microcrystalline cellulose in extrusion/spheronisation. II. Influence of drug and filler type.

Authors:  Markus Thommes; Peter Kleinebudde
Journal:  Eur J Pharm Biopharm       Date:  2005-12-01       Impact factor: 5.571

5.  Use of kappa-carrageenan as alternative pelletisation aid to microcrystalline cellulose in extrusion/spheronisation. I. Influence of type and fraction of filler.

Authors:  Markus Thommes; Peter Kleinebudde
Journal:  Eur J Pharm Biopharm       Date:  2005-12-02       Impact factor: 5.571

6.  Improved bioavailability of aceclofenac from spherical agglomerates: development, in vitro and preclinical studies.

Authors:  S Muatlik; A N Usha; M S Reddy; A K Ranjith; S Pandey
Journal:  Pak J Pharm Sci       Date:  2007-07       Impact factor: 0.684

7.  Enhancement of dissolution rate and bioavailability of aceclofenac: a chitosan-based solvent change approach.

Authors:  Srinivas Mutalik; Parambil Anju; Krishnan Manoj; Achutha Nayak Usha
Journal:  Int J Pharm       Date:  2007-09-12       Impact factor: 5.875

8.  Physicochemical characterization and dissolution enhancement of aceclofenac-hydroxypropyl beta-cyclodextrin binary systems.

Authors:  Sunita Dahiya; Kamla Pathak
Journal:  PDA J Pharm Sci Technol       Date:  2006 Nov-Dec

9.  Development of fast dispersible aceclofenac tablets: effect of functionality of superdisintegrants.

Authors:  C Mallikarjuna Setty; D V K Prasad; V R M Gupta; B Sa
Journal:  Indian J Pharm Sci       Date:  2008 Mar-Apr       Impact factor: 0.975

  9 in total
  3 in total

1.  Purification, cloning, characterization and essential amino acid residues analysis of a new ι-carrageenase from Cellulophaga sp. QY3.

Authors:  Su Ma; Gaofei Duan; Wengang Chai; Cunliang Geng; Yulong Tan; Lushan Wang; Frédéric Le Sourd; Gurvan Michel; Wengong Yu; Feng Han
Journal:  PLoS One       Date:  2013-05-31       Impact factor: 3.240

Review 2.  Carrageenan: Drug Delivery Systems and Other Biomedical Applications.

Authors:  Edisson-Mauricio Pacheco-Quito; Roberto Ruiz-Caro; María-Dolores Veiga
Journal:  Mar Drugs       Date:  2020-11-23       Impact factor: 5.118

3.  Development of a Biphasic-Release Multiple-Unit Pellet System with Diclofenac Sodium Using Novel Calcium Phosphate-Based Starter Pellets.

Authors:  Daniel Zakowiecki; Maja Frankiewicz; Tobias Hess; Krzysztof Cal; Maciej Gajda; Justyna Dabrowska; Bartlomiej Kubiak; Jadwiga Paszkowska; Marcela Wiater; Dagmara Hoc; Grzegorz Garbacz; Dorota Haznar-Garbacz
Journal:  Pharmaceutics       Date:  2021-05-28       Impact factor: 6.321

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.